Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Merck & Co., Inc. — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while Merck & Co., Inc. trades at $125.33 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals.
| JPIN | MRK | |
|---|---|---|
52-Week High | $76.96 | $129.52 |
52-Week Low | $63.14 | $77.60 |
Market Cap | — | $307.25B |
Sector | — | Health |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
MRK trades at $125.85, down 1.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30 suggesting 9% upside. Recent earnings have consistently beaten expectations, with Q1 2026 loss narrower than forecast. The company maintains strong profitability with a 73.91% gross margin and 18.97% ROE, while actively expanding its pipeline through acquisitions like Terns Pharmaceuticals.
Outlook remains positive driven by earnings beats and strategic M&A, but risks include rising debt levels and patent expirations. The stock offers a dividend yield with upcoming payment, supported by institutional accumulation. Valuation multiples are elevated, requiring sustained growth to justify current levels amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
